Opthea's Upcoming Presentations at Investment Conferences
Opthea Limited (ASX/NASDAQ: OPT) is a leading biopharmaceutical company located in Australia, dedicated to developing cutting-edge treatments for prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD). This September, the company is preparing for important engagements with investors, where it will present its latest advancements at two significant conferences.
H.C. Wainwright 26th Global Investment Conference
Opthea will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference. This presentation is scheduled for Monday at 7:00 AM ET, and will be led by Frederic Guerard, PharmD, the CEO of Opthea. This conference provides an excellent opportunity for Opthea to showcase its innovative therapies and discuss the latest progress in treatment options for retinal diseases.
Cantor 2024 Global Healthcare Conference
After the first conference, Opthea will also take part in the Cantor 2024 Global Healthcare Conference, where another presentation is set for Tuesday at 8:35 AM ET. Once again, Frederic Guerard will lead the discussion, highlighting Opthea's dedication to tackling ocular diseases with new therapeutic strategies.
Accessing the Presentations
Both presentations will be accessible for live viewing through webcasts. Interested investors can tune in via the designated channels provided by Opthea, allowing them to catch the latest insights and forecasts from the company's management team.
About Opthea and Its Innovations
Opthea stands out as a biopharmaceutical company that is committed to addressing unmet medical needs in the treatment of progressive retinal diseases. Its leading product candidate, sozinibercept, is currently under evaluation in two important Phase 3 clinical trials. These trials aim to determine the effectiveness of sozinibercept when used alongside existing anti-VEGF therapies, with the goal of improving treatment outcomes for patients experiencing vision impairment due to retinal diseases.
The results expected from these trials could potentially transform care standards and enhance the quality of life for many individuals affected by retinal diseases. By actively engaging with the investment community, Opthea aims to promote transparency and generate interest in its pioneering therapeutic developments.
Frequently Asked Questions
What is the main focus of Opthea's research?
Opthea focuses on developing innovative therapies for retinal diseases, particularly wet age-related macular degeneration and diabetic macular edema.
Who will be presenting at the conferences?
Frederic Guerard, PharmD, the CEO of Opthea, will be the presenter at both conferences.
When are the conferences taking place?
The H.C. Wainwright conference is on September 9, 2024, and the Cantor conference is on September 17, 2024.
How can investors access the presentations?
Investors can access the presentations through webcasts available on the Opthea website.
What is sozinibercept?
Sozinibercept is Opthea's lead product candidate, being investigated in Phase 3 trials to improve patient outcomes when combined with standard anti-VEGF therapies.